The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Activity of the De Novo Engineered Antimicrobial Peptide WLBU2 against Pseudomonas aeruginosa in Human Serum and Whole Blood: Implications for Systemic Applications
Open accessAbstract
Cationic amphipathic peptides have been extensively investigated as a potential source of new antimicrobials that can complement current antibiotic regimens in the face of emerging drug-resistant bacteria. However, the suppression of antimicrobial activity under certain biologically relevant conditions (e.g., serum and physiological salt concentrations) has hampered efforts to develop safe and effective antimicrobial peptides for clinical use. We have analyzed the activity and selectivity of the human peptide LL37 and the de novo engineered antimicrobial peptide WLBU2 in several biologically relevant conditions. The host-derived synthetic peptide LL37 displayed high activity against Pseudomonas aeruginosa but demonstrated staphylococcus-specific sensitivity to NaCl concentrations varying from 50 to 300 mM. Moreover, LL37 potency was variably suppressed in the presence of 1 to 6 mM Mg 2+ and Ca 2+ ions. In contrast, WLBU2 maintained its activity in NaCl and physiologic serum concentrations of Mg 2+ and Ca 2+ . WLBU2 is able to kill P. aeruginosa (10 6 CFU/ml) in human serum, with a minimum bactericidal concentration of <9 μM. Conversely, LL37 is inactive in the presence of human serum. Bacterial killing kinetic assays in serum revealed that WLBU2 achieved complete bacterial killing in 20 min. Consistent with these results was the ability of WLBU2 (15 to 20 μM) to eradicate bacteria from ex vivo samples of whole blood. The selectivity of WLBU2 was further demonstrated by its ability to specifically eliminate P. aeruginosa in coculture with human monocytes or skin fibroblasts without detectable adverse effects to the host cells. Finally, WLBU2 displayed potent efficacy against P. aeruginosa in an intraperitoneal infection model using female Swiss Webster mice. These results establish a potential application of WLBU2 in the treatment of bacterial sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Cathelicidins - a family of multifunctional antimicrobial peptides
Bals, R., & Wilson, J. M. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-2186-9 · Cited by 427
Cited by
Antibacterial peptides for therapeutic use: obstacles and realistic outlook
MARR, A., GOODERHAM, W., & HANCOCK, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.006 · Cited by 1,051
Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action
Chan, D. I., Prenner, E. J., & Vogel, H. J. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.04.006 · Cited by 1,039
Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces
Costa, F., Carvalho, I. F., Montelaro, R. C., Gomes, P., & Martins, M. C. L. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2010.11.005 · Cited by 627
Self-citationAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Membrane targeting cationic antimicrobial peptides
Ciumac, D., Gong, H., Hu, X., & Lu, J. R. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.10.103 · Cited by 351
Metadata
- Authors
- Deslouches, B., Islam, K., Craigo, J. K., Paranjape, S. M., Montelaro, R. C., & Mietzner, T. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2005-08
- Volume
- 49
- Issue
- 8
- Pages
- 3208-3216
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2152466791
- Cited by
- 159
- References
- 2
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of the De Novo Engineered Antimicrobial Peptide WLBU2 against Pseudomonas aeruginosa in Human Serum and Whole Blood: Implications for Systemic Applications. https://app.cochat.ai/papers/10.1128/aac.49.8.3208-3216.2005
- The paper
- Deslouches, B., Islam, K., Craigo, J. K., Paranjape, S. M., Montelaro, R. C., & Mietzner, T. A. (2005). Activity of the De Novo Engineered Antimicrobial Peptide WLBU2 against Pseudomonas aeruginosa in Human Serum and Whole Blood: Implications for Systemic Applications. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.49.8.3208-3216.2005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.